Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4(+) T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
In the citing paper
“The immunogenic i.m. route was chosen for these experiments, as hepatic gene transfer typically results in tolerance induction to FIX (24, 38).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Expression of DTR under XCR1 promoter allowed specific depletion of XCR1+ DCs by administration of diphtheria toxin (DT) whereas expression of fluorescent protein allowed their easy detection and tracking.”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Fortunately, the immune response is not always against AAV-mediated gene transfer, evidenced by induction of regulatory T cells (Tregs) that suppress immune response and facilitate sustained transgene expression (34, 35).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Self-citationInduction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846 · cited 7×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialRoncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814 · cited 6×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialLimmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“Liver transplants are often not rejected even across MHC barriers, and LSECs have been shown to represent specialized APCs that can induce T cell tolerance (40, 42).”
BackgroundLocal control of the immune response in the liver
Knolle, P. A., & Gerken, G. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017408.x · Cited by 603 · cited 3×
“) promotes tolerance rather than immunity to the transgene product (40).”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554 · cited 3×
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundSelf-citationAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“AAV vector (serotype 2) was produced by triple transfection of HEK-293 cells, purified by CsCl-gradient centrifugation, and quantitated by dot blot hybridization as described (23).”
MethodNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“IX as designed by Kay and colleagues (22).”
MethodJooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 5×
“Even with a ubiquitous promoter, hepatocytes are the major site of F.IX synthesis following portal infusion of AAV vector, which has a strong tropism for liver and does not appear to transduce other cell types within the liver or APCs (24, 43, 44).”
BackgroundInfluential
Research works printed but not linked: 2
- Manno, C.S., et al. 2003. A phase I safety study in patients with severe hemophilia B using adeno-associated viral (AAV) vector to deliver the gene for human factor IX to skeletal muscle. Blood . In press.
- Nakai, H., et al. 2000. A proposed rAAV-liver directed clinical trial for hemophilia B. Blood. 96 (Suppl.):798a-799a.
Cited by
Items 201–300 of 471
Gene Therapy of Storage Disorders by Retroviral and Lentiviral Vectors
Biffi, A., & Naldini, L. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1133 · Cited by 45
In Vivo Model Systems for Hepatitis B Virus Research
Ortega‐Prieto, A. M., Cherry, C. J., Gunn, H., & Dorner, M. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00223 · Cited by 42
Jayandharan, G. R., Zhong, L., Sack, B. K., Rivers, A. E., Li, M., Li, B., Herzog, R. W., & Srivastava, A. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.100 · Cited by 38
“Plasma samples were obtained by retro-orbital bleeding and analyzed for hF.IX expression by enzyme-linked immunosorbent assay (ELISA) as described previously (Mingozzi et al. , 2003).”
Self-citationTranslational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs
Nichols, T. C., Whitford, M. H., Arruda, V. R., Stedman, H. H., Kay, M. A., & High, K. A. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/hum.2014.153 · Cited by 38
Self-citationAAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
Self-citationSawamoto, K., Karumuthil‐Melethil, S., Khan, S. A., Stapleton, M., Bruder, J. T., Danos, O., & Tomatsu, S. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.015 · Cited by 39
In vivo induction of regulatory T cells for immune tolerance in hemophilia
Wang, X., Terhorst, C., & Herzog, R. W. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.10.001 · Cited by 39
“Depending on the type of DC and its activation state, naive T cells may differentiate into Treg or Teff cells [95].”
BackgroundInfluentialSelf-citationMeasuring Immune Responses to Recombinant AAV Gene Transfer
Martino, A. T., Herzog, R. W., Anegon, I., & Adjali, O. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_11 · Cited by 36
Self-citationXu, L., Mei, M., Haskins, M. E., Nichols, T. C., O’Donnell, P., Cullen, K., Dillow, A. M., Bellinger, D. A., & Ponder, K. P. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.09.010 · Cited by 37
“One is to achieve high levels of expression, which reduces the chance of an immune response compared with low expression [9] [10].”
BackgroundButterfield, J. S. S., Yamada, K., Bertolini, T. B., Syed, F., Kumar, S. R. P., Li, X., Arisa, S., Piñeros, A. R., Tapia, A., Rogers, C. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.005 · Cited by 36
Self-citationGene therapy for hemophilia: past, present and future
George, L. A., & Fogarty, P. F. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.002 · Cited by 37
Annoni, A., Battaglia, M., Follenzi, A., Lombardo, A., Sergi, L. S., Naldini, L., & Roncarolo, M. (2007) · Blood · doi:10.1182/blood-2006-11-059873 · Cited by 36
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
Self-citationWolff, L. J., Wolff, J. A., & Sebestyén, M. G. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.088 · Cited by 37
Preclinical and clinical gene therapy for haemophilia
Chuah, M., Collen, D., & VandenDriessche, T. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00984.x · Cited by 36
van der Wegen, P., Louwen, R., Imam, A., Buijs‐Offerman, R. M., Sinaasappel, M., Grosveld, F. G., & Scholte, B. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.022 · Cited by 39
Ishiwata, A., Mimuro, J., Mizukami, H., Kashiwakura, Y., Takano, K., Ohmori, T., Madoiwa, S., Ozawa, K., & Sakata, Y. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1391 · Cited by 36
Guen, V. L., Judor, J., Boeffard, F., Gauttier, V., Ferry, N., Soulillou, J., Brouard, S., & Conchon, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.019 · Cited by 35
Gene therapy for hemophilia: an imperative to succeed
Hough, C. A., & Lillicrap, D. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01401.x · Cited by 38
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“Early studies in inhibitor-prone mice with large FIX gene deletions demonstrated that AAV liver gene therapy could induce immune tolerance, though the efficacy was strain dependent [71].”
BackgroundSelf-citationInnovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
“Studies in Fas-deficient mice suggested that Treg induction and T-cell deletion were both required for robust tolerance induction (79, 84).”
BackgroundSelf-citationDevelopment of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B
Brown, H. C., Doering, C. B., Herzog, R. W., Ling, C., Markusic, D. M., Spencer, H. T., Srivastava, A., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.099 · Cited by 34
“Hemophilia B mice (C3H/HeJ-F9) with a targeted deletion of murine F9 have been bred on the C3H/HeJ background for >20 generations.(26) Hemophilia B mice were injected with 1 · 10(9)–1 · 10(10) vgs of an scAAV8-F9Padua vector in the tail vein and followed over time as indicated.”
MethodSelf-citationCao, O., Armstrong, E., Schlachterman, A., Wang, L., Okita, D. K., Conti-Fine, B., High, K. A., & Herzog, R. W. (2006) · Blood · doi:10.1182/blood-2005-11-4668 · Cited by 34
Self-citationHow not to be seen: immune-evasion strategies in gene therapy
Zaldumbide, A., & Hoeben, R. C. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303082 · Cited by 39
BALB/c Mice Show Impaired Hepatic Tolerogenic Response Following AAV Gene Transfer to the Liver
Breous, E., Somanathan, S., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.301 · Cited by 33
Bočkor, L., Bortolussi, G., Iaconcig, A., Chiaruttini, G., Tiribelli, C., Giacca, M., Benvenuti, F., Zentilin, L., & Muro, A. F. (2017) · Gene Therapy · doi:10.1038/gt.2017.75 · Cited by 32
Anguela, X. M., Tafuro, S., Roca, C., Callejas, D., Agudo, J., Obach, M., Ribera, A., Ruzo, A., Mann, C. J., Casellas, A., et al. (2013) · Diabetes · doi:10.2337/db11-1776 · Cited by 35
“In contrast, after HTV injection of a plasmid expressing GFP under the control of a hepatocyte-specific promoter (hAAT) (18), only GFP hepatocytes (but not KCs) were detected (Fig.”
Gene therapy for hemophilia: Progress to date and challenges moving forward
Gollomp, K. L., Doshi, B. S., & Arruda, V. R. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.012 · Cited by 35
Self-citationB cell–activating factor modulates the factor VIII immune response in hemophilia A
Doshi, B. S., Rana, J., Castaman, G., Shaheen, M. A., Kaczmarek, R., Butterfield, J. S. S., Meeks, S. L., Leissinger, C., Biswas, M., & Arruda, V. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142906 · Cited by 33
Self-citationUpdate on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
High, K. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.466 · Cited by 32
Self-citationLiao, G., O’Keeffe, M. S., Wang, G., van Driel, B., Malefyt, R. D. W., Reinecker, H., Herzog, R. W., & Terhorst, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00035 · Cited by 32
Self-citationHemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
“33,83 These liver-directed preclinical gene therapy studies justified the use of AAV vectors in a phase 1 clinical trial in patients suffering from severe hemophilia B.”
TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
Kumar, S. R. P., Biswas, M., Cao, D., Arisa, S., Muñoz-Melero, M., Lam, A. K., Piñeros, A. R., Kapur, R., Kaisho, T., Kaufman, R. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.029 · Cited by 31
“15,31 Counterintuitively, low levels of expression may elicit a cytotoxic T cell response, resulting in loss of expression.”
Self-citationFoley, J. W., Bercury, S. D., Finn, P. F., Cheng, S. H., Scheule, R. K., & Ziegler, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.110 · Cited by 31
Recent Progress in Gene Therapy for Hemophilia
Chuah, M., Nair, N., & VandenDriessche, T. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.088 · Cited by 34
“, 2006) and that liver-directed approaches by result in Treg induction and clotting factor– specific immune tolerance (Mingozzi et al., 2003).”
InfluentialSelot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“lin class switching, affinity maturation and production of IgG subclasses [103] [104] [105] via plasma cells [98].”
Wang, X., Moghimi, B., Zolotukhin, I., Morel, L. M., Cao, O., & Herzog, R. W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.43 · Cited by 31
Self-citationPreclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 36
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 37
“…several other studies showing the protolerogenic properties of hepatic transgene expression, mediated by various mechanisms, including the induction of antigen-specific regulatory T cells (Tregs, CD4 + CD25 + FOXP3 + ) and the depletion of antigen-reactive CD4 + T helper cells (Th) 119,121,122 (Fig.”
Self-citationCarpentier, M., Lorain, S., Chappert, P., Lalfer, M., Hardet, R., Urbain, D., Peccate, C., Adriouch, S., Garcia, L., Davoust, J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.235 · Cited by 25
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
“IX in four different strains of mice using an AAV2 vector with an ubiquitous EF1α promoter or a liver-specific ApoE enhancer/α1-antitrypsin (ApoE/hAAT) promoter [44].”
MethodSelf-citationRick, M. E., Walsh, C., & Key, N. S. (2003) · Hematology · doi:10.1182/asheducation-2003.1.559 · Cited by 31
Modeling hepatitis B virus infection, immunopathology and therapy in mice
Cheng, L., Li, F., Bility, M. T., Murphy, C. M., & Su, L. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.012 · Cited by 31
“In addition, in vivo hepatic gene transfer through AAV vectors can induce immune tolerance to the transgene (Mingozzi et al., 2003).”
BackgroundTowards the clinical translation of optogenetic skeletal muscle stimulation
Gundelach, L. A., Hüser, M. A., Beutner, D., Ruther, P., & Bruegmann, T. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02387-0 · Cited by 30
“While AAV vector delivery to the liver seems to induce transgene tolerance in many cases [91, 100, 167], prolonged transgene expression following intramuscular AAV delivery required immunosuppression in several preclinical trials [42, 48, 51, 154].”
BackgroundAshrani, A. A., Reding, M. T., Shet, A. S., Osip, J., Humar, A., Lake, J. R., & Key, N. S. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.01030.x · Cited by 30
The immune response to the fVIII gene therapy in preclinical models
Patel, S. R., Lundgren, T. S., Spencer, H. T., & Doering, C. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00494 · Cited by 29
“Similarly, several studies demonstrate that gene transfer of human fIX using liver-tropic AAV promotes generation of Tregs that have the capacity to suppress antibody formation to human fIX following transfer into naïve hemophilia B mice (71, 79, 80).”
BackgroundGene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation
Scott, D. W., & Lozier, J. N. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08925.x · Cited by 34
“Gene therapy for haemophilia with AAV vectors is most efficient with hepatic delivery (Mingozzi et al. 2003).”
BackgroundAdeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity
Mingozzi, F., & Büning, H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00120 · Cited by 31
“These responses in fact can be desirable when they result in induction of tolerance to the therapeutic transgene (9), or when they are exploited for vaccine development, as discussed by Nieto and Salvetti in their review article (10).”
BackgroundSelf-citationBiswas, M., Palaschak, B., Kumar, S. R. P., Rana, J., & Markusic, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01293 · Cited by 28
“Hemophilia B mice with a targeted deletion of murine F9 have been bred on BALB/c background for >10 generations (14).”
BackgroundCarpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Pan‐Castillo, B., Fafián‐Labora, J., Mitchell, T. P., Yuste, A., Öğrünç, M., Nightingale, T. D., Mayán, M. D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04569-3 · Cited by 32
“Importantly, F9 expression can induce regulatory CD4 T cells in mice suggesting a role for F9 in immunosurveillance [44].”
BackgroundBarbon, E., Aymé, G., Mohamadi, A., Ottavi, J., Kawecki, C., Casari, C., Verhenne, S., Marmier, S., van Wittenberghe, L., Charles, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911298 · Cited by 29
“As it is well established that the liver expression of a protein is associated with induction of immune tolerance (Mingozzi et al, 2003; Puzzo et al, 2017), we expressed our sdAb under the control of a strong constitutive promoter known to drive immunogenicity (Colella et al, 2019) and expressed it…”
BackgroundSelf-citationMuscle‐directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors
Wang, L., Louboutin, J. P., Bell, P. L., Greig, J. A., LI, Y., WU, D., & Wilson, J. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04491.x · Cited by 33
Immunomodulatory Gene Therapy in Lysosomal Storage Disorders
Koeberl, D. D., & Kishnani, P. S. (2009) · Current Gene Therapy · doi:10.2174/156652309790031094 · Cited by 29
“Acquisition of tolerance to FIX required induction of regulatory CD4+ T cells, most likely CD4+CD25+ Treg cells, which suppressed neutralizing antibody formation [51].”
BackgroundPicanço‐Castro, V., Heinz, S., Bott, D., Behrmann, M., Covas, D. T., Seifried, E., & Tonn, T. (2007) · Cytotherapy · doi:10.1080/14653240701656053 · Cited by 27
Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome
Bortolussi, G., & Muro, A. F. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1495558 · Cited by 31
Poupiot, J., Costa Verdera, H., Hardet, R., Colella, P., Collaud, F., Bartolo, L., Davoust, J., Sanatine, P., Mingozzi, F., Richard, I., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.012 · Cited by 24
Self-citationGene therapy progress and prospects: the skin – easily accessible, but still far away
Hengge, U. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302855 · Cited by 27
Immunology of Neonatal Gene Transfer
Ponder, K. P. (2007) · Current Gene Therapy · doi:10.2174/156652307782151434 · Cited by 27
“In contrast, both clonal deletion and Treg cells contributed to tolerance development after gene therapy to adults [Mingozzi et al., 2003; Cao et al., 2007].”
BackgroundThe deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Lytle, A. M., Brown, H. C., Paik, N. Y., Knight, K. A., Wright, J. F., Spencer, H. T., & Doering, C. B. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.56 · Cited by 25
Kelly, M., Zhuo, J., Bharadwaj, A. S., & Chao, H. (2009) · Molecular Therapy · doi:10.1038/mt.2009.25 · Cited by 26
Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice
Pontoizeau, C., Sola, M. S., Gaborit, C., Nguyen, V., Rotaru, I., Tual, N., Colella, P., Girard, M., Biferi, M. G., Arnoux, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30880-w · Cited by 26
Self-citationGene therapy approaches for stem cell protection
Greenberger, J. S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303004 · Cited by 25
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
Bartolo, L., Li Chung Tong, S., Chappert, P., Urbain, D., Collaud, F., Colella, P., Richard, I., Ronzitti, G., Demengeot, J., Gross, D. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127008 · Cited by 23
“Taking into account prior knowledge from coagulation hFIX studies evidencing the immunological benefits of liver transduction for hFIX tolerance induction (31, 38), we devised a dual muscle-liver transduction protocol able to impose transgene-specific immunological unresponsiveness for muscle transgene.”
BackgroundMethodResultSelf-citationCotugno, G., Tessitore, A., Capalbo, A., Annunziata, P., Strisciuglio, C., Faella, A., Aurilio, M., Tommaso, M. D., Russo, F., Mancini, A., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.189 · Cited by 25
“This was unexpected because AAV-mediated, liver-restricted gene transfer has been re-ported to induce tolerance to secreted proteins in null animals (Mingozzi et al. , 2003; Franco et al. , 2005; Passini et al. , 2007).”
Hengge, U. R., & Bardenheuer, W. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30038 · Cited by 25
“This situation, in turn requires the development of immunosuppressive treatment strategies, when retroviral vectors are used, as has been successfully performed in liver-mediated gene therapy [Mingozzi et al., 2003].”
Animal models of HBV infection
Dandri, M., & Petersen, J. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.04.014 · Cited by 29
Haemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 28
Craeyveld, E. V., Lievens, J., Jacobs, F., Feng, Y., Snoeys, J., & Geest, B. D. (2009) · Gene Therapy · doi:10.1038/gt.2009.8 · Cited by 24
Sternberg, A. R., Martos-Rus, C., Davidson, R. J., Liu, X., & George, L. A. (2024) · Nature Communications · doi:10.1038/s41467-024-51296-8 · Cited by 24
“Commensurate with the ability of liver-directed gene transfer to induce tolerance 49,50 , all inhibitor-positive AAV-treated HA/pF8 mice tolerized (Fig.”
BackgroundHuang, W., McMurphy, T. B., Liu, X., Wang, C., & Cao, L. (2016) · Molecular Therapy · doi:10.1038/mt.2016.34 · Cited by 24
“a minimal promoter region of α-1antitrypsin coupled with the enhancer element of the ApoE gene (33).”
BackgroundKolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713478629 · Cited by 23
Gernoux, G., Guilbaud, M., Dubreil, L., Larcher, T., Babarit, C., Ledevin, M., Jaulin, N., Planel, P., Moullier, P., & Adjali, O. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.070 · Cited by 23
“15,16 5–9,17 Overall, what Todate, rAAV-mediated transduction of APCs was demonstrated only ex vivo using either monocyte or bone marrow-derived DCs. 29 The level of DC transduction and activation was shown in two studies to be even sufficient to vaccinate mice after in vivo delivery with the…”
InfluentialThe gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.375.3797885 · Cited by 23
Self-citationValentino, L. A., Ozelo, M. C., Herzog, R. W., Key, N. S., Pishko, A. M., Ragni, M. V., Samelson‐Jones, B. J., & Lillicrap, D. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.05.011 · Cited by 21
Self-citationCotugno, G., Annunziata, P., Barone, M. V., Karali, M., Banfi, S., & Auricchio, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033286 · Cited by 22
“Neutralizing humoral immune responses to a secreted transgene product has often limited the efficacy of liver-directed gene transfer [14,15,26,55,56].”
BackgroundAdeno‐Associated Virus Vector–Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver
Junge, N., Mingozzi, F., Ott, M., & Baumann, U. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000703 · Cited by 23
Self-citationFrench, R. A., Samelson-Jones, B. J., Niemeyer, G. P., Lothrop, C. D., Merricks, E. P., Nichols, T. C., & Arruda, V. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015313 · Cited by 21
Self-citationGene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Domvri, K., Zarogoulidis, P., Porpodis, Κ., Koffa, M. D., Lambropoulou, M., Kakolyris, S., Kolios, G. C., Zarogoulidis, P., & Chatzaki, Ε. (2012) · Current Gene Therapy · doi:10.2174/156652312803519788 · Cited by 24
“AAV vectors offer a more promising alternative, as they are capable of maintaining high levels of hepatic transgene expression for prolonged periods of time, particularly when regulated by tissue-specific enhancers and promoters [39-41].”
BackgroundBioanalysis of Adeno-Associated Virus Gene Therapy Therapeutics: Regulatory Expectations
Gorovits, B., Marshall, J.-C. A., Smith, J., Whiteley, L. O., & Neubert, H. (2019) · Bioanalysis · doi:10.4155/bio-2019-0135 · Cited by 22
Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy
Colella, P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00733-x · Cited by 24
“The ability of most AAVs to transduce the liver at relatively low vector doses [76–78] and to induce hepatic-mediated immune tolerance to transgene-encoded proteins [79], including GAA [80–83], are two key advantages of this approach.”
Chu, Q., Joseph, M. F., Przybylska, M., Yew, N. S., & Scheule, R. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.007 · Cited by 20
Callahan, S. M., Boquet, M. P., Ming, X., Brunner, L. J., & Croyle, M. A. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.884 · Cited by 20
Palaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.004 · Cited by 19
Self-citationCurrent avenues of gene therapy in Pompe disease
Leon‐Astudillo, C., Trivedi, P. D., Sun, R. C., Gentry, M. S., Fuller, D. D., Byrne, B. J., & Corti, M. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001187 · Cited by 24
“Remarkably, the liver can secrete high levels of engineered proteins and can serve as a depot for secretion of rhGAA [54].”
BackgroundEvaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, D. M., Nichols, T. C., Merricks, E. P., Palaschak, B., Zolotukhin, I., Marsic, D., Zolotukhin, S., Srivastava, A., & Herzog, R. W. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1200-1 · Cited by 19
“Male hemophilia B mice on a BALB/c background (BALB/c-F9−/Y) are bred onsite and have a targeted deletion of the murine F9 gene [22, 23].”
Self-citationKraszewska, I., Tomczyk, M., Andrysiak, K., Biniecka, M., Geisler, A., Fechner, H., Zembala, M. O., Stępniewski, J., Dulak, J., & Jaźwa, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.006 · Cited by 19
Genetic Targeting of the Albumin Locus to Treat Hemophilia
Davidoff, A. M., & Nathwani, A. C. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1600347 · Cited by 19
Update on gene therapy for hereditary hematological disorders
Herzog, R. W., & Arruda, V. R. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.2.215 · Cited by 20
Self-citationCousens, L. P., Mingozzi, F., van der Marel, S., Su, Y. A., Garman, R. D., Ferreira, V., Martin, W. D., Scott, D. W., & Groot, A. S. D. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21405 · Cited by 18
Self-citationHan, S.-O., Li, S., Bird, A., & Koeberl, D. D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.033 · Cited by 18
“…for hemophilia, each of which might be adapted to the treatment of Pompe disease, including (1) liver-specific expression of therapeutic genes, 29,30 (2) neonatal exposure to the protein, 31,32 (3) expression of the therapeutic gene in precursor forms of immunologic cells 33 or in tolerogenic…”
Suwanmanee, T., Ferris, M. T., Hu, P., Gui, T., Montgomery, S. A., de Villena, F. P., & Kafri, T. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.009 · Cited by 18
“demonstrated that induction of immune tolerance to and long-term therapeutic levels of expression of vector-delivered human factor IX were more readily achieved in C57BL/6 mice compared to BALB/c, C3H, and CD-1, although precise assessment of the genetic contributions within these studies was not characterized.(51,52)…”
BackgroundPreclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE
Parés, M., Fornaguera, C., Vila‐Julià, F., Oh, S., Fan, S. H. Y., Tam, Y. K., Comes, N., Vidal, F., Martí, R., Borrós, S., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.152 · Cited by 20
Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2014) · Biomedicines · doi:10.3390/biomedicines2020132 · Cited by 18
Wang, X., Herzog, R. W., Byrne, B. J., Kumar, S. R. P., Zhou, Q., Buchholz, C. J., & Biswas, M. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.005 · Cited by 19
“HB mice with a targeted deletion (promoter and first three exons) of murine F9 (null mutation) were bred on a BALB/c background for >10 generations.(41) Human CD20-tg BALB/c mice were a kind gift from Dr.”
MethodSelf-citationInhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
The Role of Apoptosis in Immune Hyporesponsiveness Following AAV8 Liver Gene Transfer
Faust, S. M., Bell, P., Zhu, Y., Sanmiguel, J., & Wilson, J. M. (2013) · Molecular Therapy · doi:10.1038/mt.2013.94 · Cited by 17
Kao, C., Lin, C., Yu, I., Tao, M., Wu, H., Shi, G., Yang, Y., Kao, J., & Lin, S. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0792 · Cited by 17
Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques
Greig, J. A., Nordin, J. M. L., White, J. W., Wang, Q., Bote, E., Goode, T. L., Calcedo, R., Wadsworth, S. C., Wang, L., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.080 · Cited by 17
Metadata
- Authors
- Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-01
- Volume
- 111
- Issue
- 9
- Pages
- 1347-1356
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC154443
- OpenAlex
- W4250446838
- Cited by
- 466
- References
- 44
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 17 · 2021: 16 · 2020: 19 · 2019: 21 · 2018: 24 · 2017: 29 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 17 · 2012: 23
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Hemophilia Foundation
- Hemophilia of Georgia
- National Institutes of Health (5r01hl061921-02)
- National Heart, Lung, and Blood Institute (R01 HL61921)
- National Institute of Allergy and Infectious Diseases (R01 AI/HL 51390-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune tolerance, coagulation factor IX, AAV gene delivery, hepatic gene transfer, gene replacement therapy, hemophilia B, regulatory T cells, T cell tolerance, transgene expression, secreted antigens, humoral immune response
- MeSH terms
- Dependovirus, Animals, Antibodies, Hemophilia B, Factor IX, Humans, Immune Tolerance, Liver, Mice, Inbred Strains, Promoter Regions, Genetic, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Interleukin-4, Gene Transfer Techniques, Mice, Knockout, fas Receptor, Adoptive Transfer, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.